Method of treating neurological conditions with oleandrin
Inventors
ADDINGTON, Otis C. • Newman, Robert A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9877979-B2
Publication Date
2018-01-30
Expiration Date
Abstract
A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.
Core Innovation
The disclosed invention relates to treating, improving clinical status, and preventing or reducing the incidence of neurological conditions in a subject or a population at risk. The methods include administering a therapeutically effective dose of an oleandrin-containing composition sufficient to provide a plasma concentration of oleandrin in the range of 0.005 to 10 ng/ml.
The invention further includes methods for improving the clinical status of a statistically significant number of subjects in a population having a neurological condition. In addition, the invention provides a method for reducing the incidence of occurrence of a neurological condition in a population of subjects at risk by administering the oleandrin-containing composition on a recurring basis for an extended period of time to maintain the plasma oleandrin concentration in the range of 0.005 to 10 ng/ml.
For stroke, a time-delayed method is provided in which oleandrin-containing composition is administered within an acceptable delay period after a subject has suffered the stroke. The oleandrin-containing composition is described as being used alone or further comprising one or more other therapeutically effective agents.
Claims Coverage
The provided independent claims cover four core therapeutic use categories: treatment of a neurological condition in a subject, improvement of clinical status in a population, reduction of incidence in an at-risk population, and a time-delayed stroke treatment. Across these independent claims, the shared inventive element is administering an oleandrin-containing composition to achieve plasma oleandrin in the range of 0.005 to 10 ng/ml, with certain claims further requiring statistical-population improvement, recurring administration for extended periods, or an acceptable delay period after stroke.
Treating a neurological condition via plasma oleandrin concentration range
Administering to a subject in need a therapeutically effective dose of an oleandrin-containing composition sufficient to provide a plasma concentration of oleandrin in the range of 0.005 to 10 ng/ml.
Improving clinical status of a statistically significant number of subjects
Administering to subjects in a population having a neurological condition a therapeutically effective dose of an oleandrin-containing composition sufficient to provide a plasma concentration of oleandrin in the range of 0.005 to 10 ng/ml to improve the clinical status of a statistically significant number of subjects.
Reducing incidence of a neurological condition by recurring extended administration
Administering a therapeutically effective dose of an oleandrin-containing composition on a recurring basis for an extended period of time to one or more subjects in a population of subjects at risk, where the dose provides a plasma concentration of oleandrin in the range of 0.005 to 10 ng/ml thereby reducing the incidence of the neurological condition in the population.
Time-delayed treating of stroke with plasma oleandrin concentration range
Within an acceptable delay period after a subject has suffered the stroke, administering a therapeutically effective dose of oleandrin-containing composition sufficient to provide a plasma concentration of oleandrin in the range of 0.005 to 10 ng/ml.
Across the independent claims, the claim coverage centers on achieving a specified plasma oleandrin concentration range (0.005 to 10 ng/ml) by administering an oleandrin-containing composition, applied to treatment of a neurological condition in an individual subject, improvement of clinical status in a statistically significant number of subjects, reduction of incidence in an at-risk population via recurring extended administration, and time-delayed treatment of stroke within an acceptable delay period.
Stated Advantages
Improving the clinical status of a statistically significant number of subjects in a population having a neurological condition.
Reducing the incidence of occurrence of a neurological condition in a population of subjects at risk.
Treating stroke by a time-delayed method within an acceptable delay period after suffering the stroke.
Treating a neurological condition in a subject by administering an oleandrin-containing composition.
Documented Applications
Treating neurological conditions in a subject, including stroke, Huntington’s disease, and Alzheimer’s disease.
Improving the clinical status of a statistically significant number of subjects with a neurological condition.
Reducing the incidence of neurological conditions in a population of subjects at risk by recurring administration for an extended period.
Time-delayed treatment of stroke within an acceptable delay period after the subject has suffered the stroke.
Interested in licensing this patent?